Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.
The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neuro-degenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention.
NOTE: This Patent is held by the US Department of Health and Social Services, and therefore proves the US Federal Government's classification of Cannabis as a Schedule 1 Drug (i.e. with no medical benefit) is a complete fraud !
The application relates to the identification that cannabinoids, such as cannabidol can be used to treat inflammatory diseases. Cannabinoids for use in treating inflammatory diseases, methods of treating inflammatory diseases and cannabinoids in combination with pharmaceutically acceptable carriers are claimed.
US Patent 8034843: Compositions comprising Cannabinoids for Treatment of Nausea, Vomiting, Emesis, Motion Sickness or Like Conditions
Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.
A method of treating motion sickness in a mammal comprising administering a pharmaceutically acceptable amount of, or an extract consisting essentially of a pharmaceutically acceptable amount of, CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA, wherein the amount of CBD and/or CBDA and/or the propyl variants CBDV and/or CBDVA is greater than 50% of the total cannabinoid content, wherein the CBDA, and/or CBDVA and/or CBD and/or CBDV is/are present as a cannabis extract, and wherein the cannabis extract contains less than 10% (w/w) of other cannabinoids.
The present invention relates to the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemo-therapy-induced nausea, and of anit-vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.
Use of a cannabidol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
International Patent 2009/013506: Cannabidiol for use in the Treatment of Transmissible Neurodegenerative Conditions
The present invention relates to the use of cannabidiol for use in the prevention or treatment of transmissible neurodegenerative conditions. Preferably the neurodegenerative condition to be prevented or treated is prion disease.
Surprisingly, the applicants have found that the administration of the cannabinoid cannabidiol (CBD) is efficacious in the prevention and treatment of neurodegenerative conditions. In particular it has been found that cannabidiol is useful in the prevention and treatment of prion diseases in humans and other mammals.
Cannabidiol (CBD) is a non-psychoactive component of cannabis sativa. CBD was found to inhibit the formation of PrPres in cells and exhibited neuroprotective activity against PrPres-induced neurotoxicity.
US Patent Application 2009/0197941: Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease
The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.
Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease of the airways that is characterised by a gradual loss of lung function. The term COPD is often used to describe many different pulmonary conditions including chronic bronchitis, chronic obstructive bronchitis and emphysema.
US Patent Application 2010/0035978: Combination of Cannabinoids for the Treatment of Peripheral Neuropathic Pain
The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10.
This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
A method of treating a patient comprising administering a therapeutically effective amount of a cannabis plant extract comprising a phytocannabinoid containing component and a non-phytocannabinoid containing component, wherein the phytocannabinoid containing component comprises at least 50% (w/w) of the cannabis plant extract and in which the principle is not tetrahydrocannabinol (THC) or cannabidiol (CBD), and the non-phytocannabinoid containing component comprises at least 15% (w/w) of the cannabis plant extract and further comprises a monoterpene fraction comprising a principle monoterpene which is selected from myrcenes or pinenes and a sesquiterpene fraction comprising a principle sesquiterpene which is selected from caryophyllenes or humulenes to the patient.
The present invention relates to cannabinoids for use in the treatment of neuropathic pain. Preferably the cannabinoids are one or more phytocannabinoids of: cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) or tetrahydrocannabivarin (THCV). More preferably the phytocannabinoids are isolated and/or purified from cannabis plant extracts.
Surprisingly, the applicants have found that administration of the cannabinoids cannabigerol (CBG), cannabichromene (CBC), cannabidivarin (CBDV) and tetrahydrocannabivarin (THCV) are effective in the treatment of an animal model of neuropathic pain.